Institution
University of Bologna
Education•Bologna, Emilia-Romagna, Italy•
About: University of Bologna is a education organization based out in Bologna, Emilia-Romagna, Italy. It is known for research contribution in the topics: Population & Galaxy. The organization has 38387 authors who have published 115176 publications receiving 3460869 citations. The organization is also known as: Università di Bologna & UNIBO.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Using a new survey of more than 10,000 faint galaxies, the anisotropy parameter β = 0.70 ± 0.26 is measured, which is consistent with the standard cosmological-constant model with low matter density and flat geometry, although the error bars are still too large to distinguish among alternative origins for the accelerated expansion.
Abstract: Observations of distant supernovae indicate that the Universe is now in a phase of accelerated expansion the physical cause of which is a mystery. Formally, this requires the inclusion of a term acting as a negative pressure in the equations of cosmic expansion, accounting for about 75 per cent of the total energy density in the Universe. The simplest option for this "dark energy" corresponds to a cosmological constant, perhaps related to the quantum vacuum energy. Physically viable alternatives invoke either the presence of a scalar field with an evolving equation of state, or extensions of general relativity involving higher-order curvature terms or extra dimensions. Although they produce similar expansion rates, different models predict measurable differences in the growth rate of large-scale structure with cosmic time. A fingerprint of this growth is provided by coherent galaxy motions, which introduce a radial anisotropy in the clustering pattern reconstructed by galaxy redshift surveys. Here we report a measurement of this effect at a redshift of 0.8. Using a new survey of more than 10,000 faint galaxies, we measure the anisotropy parameter b = 0.70 +/- 0.26, which corresponds to a growth rate of structure at that time of f = 0.91 +/- 0.36. This is consistent with the standard cosmological-constant model with low matter density and flat geometry, although the error bars are still too large to distinguish among alternative origins for the accelerated expansion. This could be achieved with a further factor-of-ten increase in the sampled volume at similar redshift.
690 citations
•
08 Nov 2007TL;DR: A lack of statistical information at the firm level has so far prevented the systematic inclusion of firm-level analysis in the policymaker's standard toolbox as mentioned in this paper, and their analysis reveals some new facts that are simply unobservable at the aggregate level.
Abstract: Policymakers tend to view the internationalisation of firms from the perspective of export, import and FDI statistics. A lack of statistical information at the firm level has so far prevented the systematic inclusion of firm-level analysis in the policymaker's standard toolbox. Some firm-level datasets are now available, however, and their analysis reveals some new facts that are simply unobservable at the aggregate level.
688 citations
••
Catholic University of the Sacred Heart1, Memorial Sloan Kettering Cancer Center2, International Agency for Research on Cancer3, University Health Network4, University of Lausanne5, Centre Hospitalier Universitaire de Grenoble6, Utrecht University7, Charité8, University of Texas MD Anderson Cancer Center9, Technische Universität München10, Belfast Health and Social Care Trust11, University of Zurich12, University of Nottingham13, Beatson West of Scotland Cancer Centre14, Tohoku University15, University of Verona16, Institut Gustave Roussy17, University of Bologna18, Radboud University Nijmegen19
TL;DR: This work believes this conceptual approach can form the basis for the next generation of NEN classifications and will allow more consistent taxonomy to understand how neoplasms from different organ systems inter-relate clinically and genetically.
688 citations
••
Stanford University1, University of Maryland, Baltimore2, Baylor College of Medicine3, University of Pittsburgh4, University of California, Los Angeles5, College of Osteopathic Medicine of the Pacific6, University of Chicago7, University of Texas at Austin8, Durham University9, University of Alabama10, Society for Women's Health Research11, University of Bologna12, Gannon University13, Brigham and Women's Hospital14, Mayo Clinic15, University of Washington16
TL;DR: There is consensus among experts regarding some indicators of sleep quality among otherwise healthy individuals, but overall, there was less or no consensus regarding sleep architecture or nap‐related variables as elements of good sleep quality.
688 citations
••
University of Turin1, Masaryk University2, University of Münster3, Sapienza University of Rome4, Monash University5, Medical University of Vienna6, Medical University of Warsaw7, University of Tübingen8, Casa Sollievo della Sofferenza9, University of Bologna10, Medical University of Białystok11, Ankara University12, Charles University in Prague13, Dresden University of Technology14, University of Ulm15, Celgene16, National and Kapodistrian University of Athens17
TL;DR: MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age.
Abstract: The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P<0.001) or MP (13 months; hazard ratio, 0.40; P <0.001). Response rates were superior with MPR-R and MPR (77% and 68%, respectively, vs. 50% with MP; P<0.001 and P = 0.002, respectively, for the comparison with MP). The progression-free survival benefit associated with MPR-R was noted in patients 65 to 75 years of age but not in those older than 75 years of age (P = 0.001 for treatment-by-age interaction). After induction therapy, a landmark analysis showed a 66% reduction in the rate of progression with MPR-R (hazard ratio for the comparison with MPR, 0.34; P<0.001) that was age-independent. During induction therapy, the most frequent adverse events were hematologic; grade 4 neutropenia was reported in 35%, 32%, and 8% of the patients in the MPR-R, MPR, and MP groups, respectively. The 3-year rate of second primary tumors was 7% with MPR-R, 7% with MPR, and 3% with MP. Conclusions MPR-R significantly prolonged progression-free survival in patients with newly di agnosed multiple myeloma who were ineligible for transplantation, with the great est benefit observed in patients 65 to 75 years of age. (Funded by Celgene; MM-015 ClinicalTrials.gov number, NCT00405756.)
688 citations
Authors
Showing all 39076 results
Name | H-index | Papers | Citations |
---|---|---|---|
Anil K. Jain | 183 | 1016 | 192151 |
H. S. Chen | 179 | 2401 | 178529 |
Stefan Schreiber | 178 | 1233 | 138528 |
Alvio Renzini | 162 | 908 | 95452 |
David H. Adams | 155 | 1613 | 117783 |
Roberto Romero | 151 | 1516 | 108321 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Paolo Boffetta | 148 | 1455 | 93876 |
Kypros H. Nicolaides | 147 | 1302 | 87091 |
J. Fraser Stoddart | 147 | 1239 | 96083 |
Fabio Finelli | 147 | 542 | 111128 |
Jack Hirsh | 146 | 734 | 86332 |
Kjell Fuxe | 142 | 1479 | 89846 |
Andrew Ivanov | 142 | 1812 | 97390 |
Peter Lang | 140 | 1136 | 98592 |